Concepedia

Publication | Open Access

Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations

DOIFull Paper Access

21

Citations

11

References

2017

Year

Makoto Nakao, Hideki Muramatsu, Yusuke Kagawa, Yuto Suzuki, Yusuke Sakai, Ryota Kurokawa, Kohei Fujita, H Sato
Anticancer Research

Abstract

High NLR and low PNI were associated with early termination of nivolumab monotherapy, suggesting they might be useful biomarkers for treatment selection.

References

YearCitations

Page 1